You are here
Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI
Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH18C0352
Agency Tracking Number: H18A-001-0004
Amount:
$149,998.00
Phase:
Phase I
Program:
STTR
Solicitation Topic Code:
DHA18A-001
Solicitation Number:
2018.0
Timeline
Solicitation Year:
2018
Award Year:
2018
Award Start Date (Proposal Award Date):
2018-06-11
Award End Date (Contract End Date):
2019-01-10
Small Business Information
301 1st Street SW, Roanoke, VA, 24011
DUNS:
627132913
HUBZone Owned:
N
Woman Owned:
Y
Socially and Economically Disadvantaged:
N
Principal Investigator
Name: Dr. Yang Xu
Phone: (434) 483-4232
Email: xuy@lunainc.com
Phone: (434) 483-4232
Email: xuy@lunainc.com
Business Contact
Name: Ms. Maggie Hudson
Phone: (434) 483-4254
Email: submissions307@lunainc.com
Phone: (434) 483-4254
Email: submissions307@lunainc.com
Research Institution
Name: Virginia Polytechnic Institute and
Contact: Linda Bucy
Address: 300 Turner Street NW
Array
Blacksbur, VA, 24061
Phone: (540) 231-5281
Type: Nonprofit college or university
Contact: Linda Bucy
Address: 300 Turner Street NW
Array
Blacksbur, VA, 24061
Phone: (540) 231-5281
Type: Nonprofit college or university
Abstract
Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumatically injured brain. An intranasal formulation will be developed to simplify administration and enable delivery within minutes to hours of injury, effectively minimizing the onset of secondary inflammatory responses that may be more damaging than the initial injury itself. In Phase I, Luna will demonstrate the feasibility of this delivery system using in vitro models, and in Phase II will demonstrate the functionality of these functionalized liposomes in in vivo TBI models. * Information listed above is at the time of submission. *